Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Gastrointestinal OTC Drugs Market by Product (Laxatives, Gastrointestinal Cancer Treatments, Gastric Acid Reducers, Anti-Diarrheal, Proton Pump Inhibitors, H2 Inhibitors, Gastric Acid Neutralizers, Bowel Anti-Inflammatory, Anti-Emetics), by Indication (Gastroesophageal Reflux Disease (GERD) or Heartburn, Constipation, Diarrhea, Motion Sickness, Flatulence) and by End User (Clinics, Pharmacies, Hospitals, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03191

Pages: NA

Charts: NA

Tables: NA

Gastrointestinal diseases include complications related to the stomach, esophagus, large intestine, small intestine, gallbladder, rectum, liver, and pancreas. Gastrointestinal over the counter (OTC) drugs are medications that can be bought without any doctors prescription and are used to control vomiting, constipation, diarrhea, and flatulence.

The major factors that contribute to the growth of the gastrointestinal OTC drugs market include the increasing prevalence of gastrointestinal diseases, high adoption of OTC drugs as they are cost-effective & convenient to buy, advancements in R&D activities such as innovations in drugs, and high demand for self-diagnosis and self-medication. However, factors such as stringent government regulations and inadequate reimbursements provided for gastrointestinal OTC drugs hinder the market growth. Conversely, growth in public awareness and increase in healthcare expenditures are expected to provide numerous opportunities for the market growth in the near future.

The global gastrointestinal OTC drugs market is segmented on the basis of product, indication, end user, and region. On the basis of product, the market is segmented into laxatives, gastrointestinal cancer treatments, gastric acid reducers, anti-diarrheal, proton pump inhibitors, H2 inhibitors, gastric acid neutralizers, bowel anti-inflammatory, and anti-emetics. On the basis of indication, the market is segmented into gastroesophageal reflux disease (GERD) or heartburn, constipation, diarrhea, motion sickness, and flatulence. On the basis of end user, it is categorized into clinics, pharmacies, hospitals, and others. Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operate in this market include Johnson & Johnson, GlaxoSmithKline Plc., Bayer AG, Sanofi, Abbott Laboratories, Pfizer Inc., Prestige Brands, Inc., Boehringer Ingelheim GmbH, Procter & Gamble, and Purdue Pharma L.P.

Key Benefits

  • The study provides an in-depth analysis of the global gastrointestinal OTC drugs market with current trends and future estimations to elucidate imminent investment pockets.
  • The report provides information about the current and upcoming trends in the global gastrointestinal OTC drugs market which helps determine prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the global gastrointestinal OTC drugs market has been provided.
  • Identification of factors that are instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale have been provided.
  • Key market players within the market have been profiled in this report and their strategies thoroughly analyzed, which help understand the competitive outlook of the global gastrointestinal OTC drugs market.

 Key Market Segments

  • By Product
    • Laxatives
    • Gastrointestinal Cancer Treatments
    • Gastric Acid Reducers
    • Anti-Diarrheal
    • Proton Pump Inhibitors
    • H2 Inhibitors
    • Gastric Acid Neutralizers
    • Bowel Anti-Inflammatory
    • Anti-Emetics
  • By Indication
    • Gastroesophageal Reflux Disease (GERD) or Heartburn
    • Constipation
    • Diarrhea
    • Motion Sickness
    • Flatulence
  • By End User
    • Clinics
    • Pharmacies
    • Hospitals
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Sanofi
  • GlaxoSmithKline Plc.
  • Purdue Pharma L.P
  • Procter & Gamble
  • Prestige Brands, Inc.
  • Abbott Laboratories
  • Boehringer Ingelheim GmbH
  • Pfizer Inc.
  • Johnson & Johnson
  • Bayer AG

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: GASTROINTESTINAL OTC DRUGS MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Laxatives

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Gastrointestinal Cancer Treatments

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Gastric Acid Reducers

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Anti-Diarrheal

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Proton Pump Inhibitors

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. H2 Inhibitors

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Gastric Acid Neutralizers

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. Bowel Anti-Inflammatory

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

    • 4.10. Anti-Emetics

      • 4.10.1. Key Market Trends, Growth Factors and Opportunities

      • 4.10.2. Market Size and Forecast, By Region

      • 4.10.3. Market Share Analysis, By Country

  • CHAPTER 5: GASTROINTESTINAL OTC DRUGS MARKET, BY INDICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Indication

    • 5.2. Gastroesophageal Reflux Disease (GERD) Or Heartburn

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Constipation

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Diarrhea

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Motion Sickness

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Flatulence

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: GASTROINTESTINAL OTC DRUGS MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Clinics

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Pharmacies

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Hospitals

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: GASTROINTESTINAL OTC DRUGS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product

      • 7.2.3. Market Size and Forecast, By Indication

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Gastrointestinal Otc Drugs Market

        • 7.2.6.1. Market Size and Forecast, By Product
        • 7.2.6.2. Market Size and Forecast, By Indication
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Gastrointestinal Otc Drugs Market

        • 7.2.7.1. Market Size and Forecast, By Product
        • 7.2.7.2. Market Size and Forecast, By Indication
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Gastrointestinal Otc Drugs Market

        • 7.2.8.1. Market Size and Forecast, By Product
        • 7.2.8.2. Market Size and Forecast, By Indication
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product

      • 7.3.3. Market Size and Forecast, By Indication

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Gastrointestinal Otc Drugs Market

        • 7.3.6.1. Market Size and Forecast, By Product
        • 7.3.6.2. Market Size and Forecast, By Indication
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Gastrointestinal Otc Drugs Market

        • 7.3.7.1. Market Size and Forecast, By Product
        • 7.3.7.2. Market Size and Forecast, By Indication
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Gastrointestinal Otc Drugs Market

        • 7.3.8.1. Market Size and Forecast, By Product
        • 7.3.8.2. Market Size and Forecast, By Indication
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Gastrointestinal Otc Drugs Market

        • 7.3.9.1. Market Size and Forecast, By Product
        • 7.3.9.2. Market Size and Forecast, By Indication
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Gastrointestinal Otc Drugs Market

        • 7.3.10.1. Market Size and Forecast, By Product
        • 7.3.10.2. Market Size and Forecast, By Indication
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Gastrointestinal Otc Drugs Market

        • 7.3.11.1. Market Size and Forecast, By Product
        • 7.3.11.2. Market Size and Forecast, By Indication
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Gastrointestinal Otc Drugs Market

        • 7.3.12.1. Market Size and Forecast, By Product
        • 7.3.12.2. Market Size and Forecast, By Indication
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product

      • 7.4.3. Market Size and Forecast, By Indication

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Gastrointestinal Otc Drugs Market

        • 7.4.6.1. Market Size and Forecast, By Product
        • 7.4.6.2. Market Size and Forecast, By Indication
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Gastrointestinal Otc Drugs Market

        • 7.4.7.1. Market Size and Forecast, By Product
        • 7.4.7.2. Market Size and Forecast, By Indication
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Gastrointestinal Otc Drugs Market

        • 7.4.8.1. Market Size and Forecast, By Product
        • 7.4.8.2. Market Size and Forecast, By Indication
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Gastrointestinal Otc Drugs Market

        • 7.4.9.1. Market Size and Forecast, By Product
        • 7.4.9.2. Market Size and Forecast, By Indication
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Gastrointestinal Otc Drugs Market

        • 7.4.10.1. Market Size and Forecast, By Product
        • 7.4.10.2. Market Size and Forecast, By Indication
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Gastrointestinal Otc Drugs Market

        • 7.4.11.1. Market Size and Forecast, By Product
        • 7.4.11.2. Market Size and Forecast, By Indication
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Gastrointestinal Otc Drugs Market

        • 7.4.12.1. Market Size and Forecast, By Product
        • 7.4.12.2. Market Size and Forecast, By Indication
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Gastrointestinal Otc Drugs Market

        • 7.4.13.1. Market Size and Forecast, By Product
        • 7.4.13.2. Market Size and Forecast, By Indication
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Gastrointestinal Otc Drugs Market

        • 7.4.14.1. Market Size and Forecast, By Product
        • 7.4.14.2. Market Size and Forecast, By Indication
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product

      • 7.5.3. Market Size and Forecast, By Indication

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Gastrointestinal Otc Drugs Market

        • 7.5.6.1. Market Size and Forecast, By Product
        • 7.5.6.2. Market Size and Forecast, By Indication
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Gastrointestinal Otc Drugs Market

        • 7.5.7.1. Market Size and Forecast, By Product
        • 7.5.7.2. Market Size and Forecast, By Indication
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Gastrointestinal Otc Drugs Market

        • 7.5.8.1. Market Size and Forecast, By Product
        • 7.5.8.2. Market Size and Forecast, By Indication
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Gastrointestinal Otc Drugs Market

        • 7.5.9.1. Market Size and Forecast, By Product
        • 7.5.9.2. Market Size and Forecast, By Indication
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Gastrointestinal Otc Drugs Market

        • 7.5.10.1. Market Size and Forecast, By Product
        • 7.5.10.2. Market Size and Forecast, By Indication
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Gastrointestinal Otc Drugs Market

        • 7.5.11.1. Market Size and Forecast, By Product
        • 7.5.11.2. Market Size and Forecast, By Indication
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Johnson And Johnson

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. GlaxoSmithKline Plc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Bayer AG

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Sanofi

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Abbott Laboratories

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Pfizer Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Prestige Brands, Inc.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Boehringer Ingelheim GmbH

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Procter And Gamble

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Purdue Pharma L.P

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR LAXATIVES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR GASTROINTESTINAL CANCER TREATMENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR GASTRIC ACID REDUCERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR ANTI-DIARRHEAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR PROTON PUMP INHIBITORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR H2 INHIBITORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR GASTRIC ACID NEUTRALIZERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR BOWEL ANTI-INFLAMMATORY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR ANTI-EMETICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) OR HEARTBURN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR CONSTIPATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR DIARRHEA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR MOTION SICKNESS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR FLATULENCE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR PHARMACIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 23. NORTH AMERICA GASTROINTESTINAL OTC DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 24. NORTH AMERICA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 25. NORTH AMERICA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 26. NORTH AMERICA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. U.S. GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 28. U.S. GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 29. U.S. GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. CANADA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 31. CANADA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 32. CANADA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. MEXICO GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 34. MEXICO GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 35. MEXICO GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. EUROPE GASTROINTESTINAL OTC DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 37. EUROPE GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 38. EUROPE GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 39. EUROPE GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. FRANCE GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 41. FRANCE GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 42. FRANCE GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. GERMANY GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 44. GERMANY GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 45. GERMANY GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. ITALY GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 47. ITALY GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 48. ITALY GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. SPAIN GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 50. SPAIN GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 51. SPAIN GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. UK GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 53. UK GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 54. UK GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. RUSSIA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 56. RUSSIA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 57. RUSSIA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 58. REST OF EUROPE GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 59. REST OF EUROPE GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 60. REST OF EUROPE GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 61. ASIA-PACIFIC GASTROINTESTINAL OTC DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 62. ASIA-PACIFIC GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 63. ASIA-PACIFIC GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 64. ASIA-PACIFIC GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. CHINA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 66. CHINA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 67. CHINA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. JAPAN GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 69. JAPAN GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 70. JAPAN GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. INDIA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 72. INDIA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 73. INDIA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. SOUTH KOREA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 75. SOUTH KOREA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 76. SOUTH KOREA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 77. AUSTRALIA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 78. AUSTRALIA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 79. AUSTRALIA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 80. THAILAND GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 81. THAILAND GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 82. THAILAND GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 83. MALAYSIA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 84. MALAYSIA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 85. MALAYSIA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 86. INDONESIA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 87. INDONESIA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 88. INDONESIA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 89. REST OF ASIA PACIFIC GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 90. REST OF ASIA PACIFIC GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 91. REST OF ASIA PACIFIC GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 92. LAMEA GASTROINTESTINAL OTC DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 93. LAMEA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 94. LAMEA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 95. LAMEA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 96. BRAZIL GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 97. BRAZIL GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 98. BRAZIL GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 99. SOUTH AFRICA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 100. SOUTH AFRICA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 101. SOUTH AFRICA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 102. SAUDI ARABIA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 103. SAUDI ARABIA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 104. SAUDI ARABIA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 105. UAE GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 106. UAE GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 107. UAE GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 108. ARGENTINA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 109. ARGENTINA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 110. ARGENTINA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 111. REST OF LAMEA GASTROINTESTINAL OTC DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 112. REST OF LAMEA GASTROINTESTINAL OTC DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 113. REST OF LAMEA GASTROINTESTINAL OTC DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 114. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 115. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 116. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 117. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 118. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 120. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 121. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 122. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 123. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 124. BAYER AG: KEY EXECUTIVES
  • TABLE 125. BAYER AG: COMPANY SNAPSHOT
  • TABLE 126. BAYER AG: OPERATING SEGMENTS
  • TABLE 127. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 128. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 129. SANOFI: KEY EXECUTIVES
  • TABLE 130. SANOFI: COMPANY SNAPSHOT
  • TABLE 131. SANOFI: OPERATING SEGMENTS
  • TABLE 132. SANOFI: PRODUCT PORTFOLIO
  • TABLE 133. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 134. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 135. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 136. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 137. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 138. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 139. PFIZER INC.: KEY EXECUTIVES
  • TABLE 140. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 141. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 142. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 143. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 144. PRESTIGE BRANDS, INC.: KEY EXECUTIVES
  • TABLE 145. PRESTIGE BRANDS, INC.: COMPANY SNAPSHOT
  • TABLE 146. PRESTIGE BRANDS, INC.: OPERATING SEGMENTS
  • TABLE 147. PRESTIGE BRANDS, INC.: PRODUCT PORTFOLIO
  • TABLE 148. PRESTIGE BRANDS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 149. BOEHRINGER INGELHEIM GMBH: KEY EXECUTIVES
  • TABLE 150. BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
  • TABLE 151. BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
  • TABLE 152. BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
  • TABLE 153. BOEHRINGER INGELHEIM GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 154. PROCTER AND GAMBLE: KEY EXECUTIVES
  • TABLE 155. PROCTER AND GAMBLE: COMPANY SNAPSHOT
  • TABLE 156. PROCTER AND GAMBLE: OPERATING SEGMENTS
  • TABLE 157. PROCTER AND GAMBLE: PRODUCT PORTFOLIO
  • TABLE 158. PROCTER AND GAMBLE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 159. PURDUE PHARMA L.P: KEY EXECUTIVES
  • TABLE 160. PURDUE PHARMA L.P: COMPANY SNAPSHOT
  • TABLE 161. PURDUE PHARMA L.P: OPERATING SEGMENTS
  • TABLE 162. PURDUE PHARMA L.P: PRODUCT PORTFOLIO
  • TABLE 163. PURDUE PHARMA L.P: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL GASTROINTESTINAL OTC DRUGS MARKET
  • FIGURE 3. SEGMENTATION GASTROINTESTINAL OTC DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN GASTROINTESTINAL OTC DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALGASTROINTESTINAL OTC DRUGS MARKET
  • FIGURE 11. GASTROINTESTINAL OTC DRUGS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. GASTROINTESTINAL OTC DRUGS MARKET FOR LAXATIVES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. GASTROINTESTINAL OTC DRUGS MARKET FOR GASTROINTESTINAL CANCER TREATMENTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. GASTROINTESTINAL OTC DRUGS MARKET FOR GASTRIC ACID REDUCERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. GASTROINTESTINAL OTC DRUGS MARKET FOR ANTI-DIARRHEAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. GASTROINTESTINAL OTC DRUGS MARKET FOR PROTON PUMP INHIBITORS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. GASTROINTESTINAL OTC DRUGS MARKET FOR H2 INHIBITORS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. GASTROINTESTINAL OTC DRUGS MARKET FOR GASTRIC ACID NEUTRALIZERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. GASTROINTESTINAL OTC DRUGS MARKET FOR BOWEL ANTI-INFLAMMATORY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. GASTROINTESTINAL OTC DRUGS MARKET FOR ANTI-EMETICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. GASTROINTESTINAL OTC DRUGS MARKET SEGMENTATION, BY BY INDICATION
  • FIGURE 22. GASTROINTESTINAL OTC DRUGS MARKET FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) OR HEARTBURN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. GASTROINTESTINAL OTC DRUGS MARKET FOR CONSTIPATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. GASTROINTESTINAL OTC DRUGS MARKET FOR DIARRHEA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. GASTROINTESTINAL OTC DRUGS MARKET FOR MOTION SICKNESS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. GASTROINTESTINAL OTC DRUGS MARKET FOR FLATULENCE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. GASTROINTESTINAL OTC DRUGS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 28. GASTROINTESTINAL OTC DRUGS MARKET FOR CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 29. GASTROINTESTINAL OTC DRUGS MARKET FOR PHARMACIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 30. GASTROINTESTINAL OTC DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 31. GASTROINTESTINAL OTC DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 32. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 33. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 34. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 35. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 36. COMPETITIVE DASHBOARD
  • FIGURE 37. COMPETITIVE HEATMAP: GASTROINTESTINAL OTC DRUGS MARKET
  • FIGURE 38. TOP PLAYER POSITIONING, 2024
  • FIGURE 39. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. GLAXOSMITHKLINE PLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. BAYER AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. BAYER AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. BAYER AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. SANOFI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. SANOFI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. PRESTIGE BRANDS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. PRESTIGE BRANDS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. PRESTIGE BRANDS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 60. BOEHRINGER INGELHEIM GMBH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 61. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 62. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 63. PROCTER AND GAMBLE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 64. PROCTER AND GAMBLE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 65. PROCTER AND GAMBLE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 66. PURDUE PHARMA L.P: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 67. PURDUE PHARMA L.P: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 68. PURDUE PHARMA L.P: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Gastrointestinal OTC Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved